tiprankstipranks
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
US Market
ARCT
Arcturus Therapeutics
RESEARCH TOOLSreports

Arcturus Therapeutics (ARCT) Stock News & Sentiment

2,172 Followers
Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
Premium
Market News
Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
4d ago
WGS
ARCT
Regulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data
Premium
Company Announcements
Regulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data
1M ago
ARCT
Arcturus Therapeutics Balances Pipeline Progress With Cash Strain
Premium
Company Announcements
Arcturus Therapeutics Balances Pipeline Progress With Cash Strain
1M ago
ARCT
Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
Premium
Ratings
Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
1M ago
ARCT
Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating
Premium
Ratings
Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating
1M ago
ARCT
Options Volatility and Implied Earnings Moves Today, March 03, 2026
Premium
Market News
Options Volatility and Implied Earnings Moves Today, March 03, 2026
1M ago
AZO
BBY
ARCT Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ARCT Earnings this Week: How Will it Perform?
1M ago
ARCT
More ARCT News >

ARCT News on the Web

Cathie Wood Buys the Dip in GeneDx (WGS): 142% Upside Ahead
TipRanks News
Neutral
Roth MKM Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
TipRanks News
Neutral
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The Motley Fool
Neutral
These Are the Only 3 Stocks That Cathie Wood Bought Last Week
The Motley Fool
Neutral
Citigroup Lowers Price Target for Arcturus Therapeutics (ARCT) to $21 | ARCT Stock News
GuruFocus News
Neutral
Arcturus Therapeutics price target lowered to $21 from $66 at Canaccord
TipRanks News
Neutral
Regulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data
TipRanks News
Bearish
Arcturus Therapeutics Balances Pipeline Progress With Cash Strain
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
ARCT
Sector Average
Media Buzz
This Week1 articles
Weekly Average1 articles
News Sentiment
This Week50%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ARCT’s Media Buzz Sentiment?
1 articles about ARCT were published this week. In an average week, 1 articles are published.
    What is ARCT’s weekly average amount of articles?
    In an average week, 1 articles about ARCT are published.
      What is ARCT’s News Sentiment?
      50% of articles about ARCT were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        TXTMProText Mobility
        STAAStaar Surgical
        ALLOAllogene Therapeutics
        REPLReplimune Group
        IVVDInvivyd
        Showing the stocks with the most bullish news sentiment over the past week